We updated the design of this site on December 18, 2017. Learn more.
ClinicalTrials.gov Menu

Drug-Drug Interaction Study of TRK-100STP

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00719758
Recruitment Status : Completed
First Posted : July 22, 2008
Last Update Posted : October 13, 2008
Toray Industries, Inc
Information provided by:
Astellas Pharma Inc

July 18, 2008
July 22, 2008
October 13, 2008
June 2008
September 2008   (Final data collection date for primary outcome measure)
Pharmacokinetic profile [ Time Frame: 1 day ]
Same as current
Complete list of historical versions of study NCT00719758 on ClinicalTrials.gov Archive Site
Safety parameters (vital signs, ECG, laboratory tests) [ Time Frame: 1 day ]
Same as current
Not Provided
Not Provided
Drug-Drug Interaction Study of TRK-100STP
TRK-100STP Pharmacokinetic Study in Healthy Volunteers - Evaluation of Pharmacokinetic Interaction Between TRK-100STP and Kremezin
The purpose of this study is to evaluate the effect of AST-120 on the PK of TRK-100STP, and to evaluate the safety and tolerability of TRK-100STP alone or in combination with AST-120
Non-blinded, randomized and crossover study to evaluate pharmacokinetic interaction between TRK-100STP and AST-120 in different administration condition. Nonelderly adult volunteers will receive TRK-100STP with or without AS-T120 after meal. Safety parameters will concurrently be measured.
Phase 1
Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
  • Drug: TRK-100STP (BERASUS LA)
    Other Names:
    • beraprost
    • Careload LA
  • Drug: AST-120 (Kremezin®)
    Other Names:
    • Kremezin®
    • sopherical carbon adsorbent
Experimental: 1
Cross-over study
  • Drug: TRK-100STP (BERASUS LA)
  • Drug: AST-120 (Kremezin®)
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
September 2008
September 2008   (Final data collection date for primary outcome measure)

Inclusion Criteria:

  • Provision of written informed consent
  • Body Mass Index (BMI) of ≥17.6 to ≤26.4 kg/m2 and weight of ≥50 to ≤80 kg

Exclusion Criteria:

  • Clinical abnormal physical findings, including BP, pulse rate, ECG and laboratory assessments
  • Receives any investigational medicine within 120 days before screening
  • Recent blood donor
Sexes Eligible for Study: Male
20 Years to 44 Years   (Adult)
Contact information is only displayed when the study is recruiting subjects
Not Provided
Not Provided
Director, Astellas Pharma Inc.
Astellas Pharma Inc
Toray Industries, Inc
Study Chair: Central Contact Astellas Pharma Inc
Astellas Pharma Inc
October 2008

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP